Ginell R. Post
Professor
Also affiliated: Centre National de la Recherche Scientifique (1988); Cleveland Clinic (2000); University of Kentucky (2000–2013); Medical University of South Carolina (2008–2011); Inserm (2010); Utrecht University (2002); Université de Lille (2010); University of Arkansas Medical Center (2010–2022); Institut Pasteur de Lille (2010); University of California San Diego (1995–1997); University of Chicago (1992–1993); Arkansas Cardiology (2022); Winthrop Rockefeller Foundation (2021)
Faculty Researcher
Pathology, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Ginell R. Post's research interests are centered on hematopathology, with a specific focus on coagulopathies associated with cancer and inflammation. Dr. Post employs molecular-genetic and immunohistochemical approaches to investigate the classification and pathobiology of hematopoietic diseases.
Dr. Post's work has contributed to understanding various hematological conditions. Publications include research on Rad52's role in DNA recombination, the identification of NEK2 as a therapeutic target in lymphoma, and the immune responses induced by a P10s-PADRE vaccine in breast cancer patients. Additional studies have explored rare presentations of intestinal T-cell lymphoma, the toxicity of drug delivery agents, and the regulation of hepatic lncRNAs. Dr. Post also investigates the relationship between Hairy Cell Leukemia and severe acute respiratory distress syndrome.
With an h-index of 21 and 1,765 citations across 128 publications, Dr. Post is recognized as a highly cited researcher. Key collaborators at the University of Arkansas for Medical Sciences include Vijay Patel, Sydnye L. Shuttleworth, Samantha Kendrick, and Syed Hassan Mehdi, with whom Dr. Post shares 39 co-authored publications. Dr. Post leads an active research group and maintains a lab website.
Research Overview
My current clinical and research interests are in the area of hematopathology with focus on cancer- and inflammation-related coagulopathies and use molecular-genetic and immunohistochemical approaches to classify and understand the pathobiology of hematopoietic diseases.
Metrics
- h-index: 21
- Publications: 128
- Citations: 1,771
Selected Publications
-
Acute Myeloid Leukemia with Hemophagocytosis: Diagnostic Cues and Potential Pitfalls. (2025)PubMed OpenAlex
-
Strategies to Optimize Overutilization of Provider-Ordered Peripheral Blood Smear Review in an University Hospital Setting (2024)
-
Unexpected Presentations of Histiocytic Disorders as Mass Lesions in the Central Nervous System and Spine (2024)
Collaboration Network
Top Collaborators
- Rad52 mediates class-switch DNA recombination to IgD
- Rad52 mediates class-switch DNA recombination to IgD
- Rad52 mediates class-switch DNA recombination to IgD
- Rad52 mediates class-switch DNA recombination to IgD
- Rad52 mediates class-switch DNA recombination to IgD
- Rad52 mediates class-switch DNA recombination to IgD
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
Similar Researchers
Based on overlapping research topics